CD14 and melanoma: The INT team has been addressing the topic by developing a simplified Myeloid Index Score, i.e., a 4-marker (CD15, CD14, HLA-DR and PD-L1) flow cytometry panel to be applied in PBMC, which clearly predicts prognosis in advanced melanoma patients independently of the type of treatment (BRAF/MEK, TKI versus ICPis).